TY - GEN
T1 - Inherited endocrine diseases involving G proteins and G protein-coupled receptors
AU - Spiegel, A.
PY - 2007/12/1
Y1 - 2007/12/1
N2 - Naturally occurring mutations in the G protein Gs-α subunit and in a number of G protein-coupled receptors (GPCRs) have been identified in human diseases. Loss-offunction mutations in GPCRs for various hormones lead to hormone resistance manifest as hypofunction of the gland expressing the affected GPCR. Conversely, GPCR gain-offunction mutations lead to hormone-independent activation and hyperfunction of the involved gland. Our laboratory has focused on the extracellular calcium-sensing GPCR (CaR) expressed primarily, but not exclusively, in parathyroid glands and kidney. Loss-offunction CaR mutations lead to a form of hyperparathyroidism, an apparent exception to the general pattern described above, but in fact reflecting resistance to the normal inhibition of parathyroid hormone secretion by the 'hormone' agonist, extracellular Ca2+. CaR gain-of function-mutations cause autosomal dominant hypocalcemia due to activation of the receptor at subphysiologic concentrations of serum Ca22+, leading to 'inappropriate' inhibition of parathyroid hormone secretion. I will describe our recent work that helps inform design of novel therapeutics targeting this important GPCR.
AB - Naturally occurring mutations in the G protein Gs-α subunit and in a number of G protein-coupled receptors (GPCRs) have been identified in human diseases. Loss-offunction mutations in GPCRs for various hormones lead to hormone resistance manifest as hypofunction of the gland expressing the affected GPCR. Conversely, GPCR gain-offunction mutations lead to hormone-independent activation and hyperfunction of the involved gland. Our laboratory has focused on the extracellular calcium-sensing GPCR (CaR) expressed primarily, but not exclusively, in parathyroid glands and kidney. Loss-offunction CaR mutations lead to a form of hyperparathyroidism, an apparent exception to the general pattern described above, but in fact reflecting resistance to the normal inhibition of parathyroid hormone secretion by the 'hormone' agonist, extracellular Ca2+. CaR gain-of function-mutations cause autosomal dominant hypocalcemia due to activation of the receptor at subphysiologic concentrations of serum Ca22+, leading to 'inappropriate' inhibition of parathyroid hormone secretion. I will describe our recent work that helps inform design of novel therapeutics targeting this important GPCR.
UR - http://www.scopus.com/inward/record.url?scp=39549114335&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=39549114335&partnerID=8YFLogxK
U2 - 10.1159/000111069
DO - 10.1159/000111069
M3 - Conference contribution
C2 - 17986833
AN - SCOPUS:39549114335
SN - 9783805583473
T3 - Endocrine Development
SP - 133
EP - 144
BT - Congenital Endocrinopathies
A2 - Lorini, Renata
A2 - D'Annunzio, Giuseppe
A2 - Maghnie, Mohamad
A2 - Loche, Sandro
A2 - Savage, Martin
ER -